
June 23 (Reuters) - Leap Therapeutics Inc LPTX.O:
LEAP THERAPEUTICS REPORTS UPDATED CLINICAL DATA FROM SIREXATAMAB COLORECTAL CANCER STUDY AND ANNOUNCES EXPLORATION OF STRATEGIC ALTERNATIVES
LEAP THERAPEUTICS INC - TO REDUCE WORKFORCE BY 75%
LEAP THERAPEUTICS INC - TO EXPLORE SALE OR PARTNERSHIP FOR SIREXATAMAB AND FL-501
LEAP THERAPEUTICS INC - ESTIMATES $3.2 MILLION COST FOR WORKFORCE REDUCTION